CompletedNCT04943042
An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swedish Orphan Biovitrum
- Principal Investigator
- Nina Skuban, MDSwedish Orphan Biovitrum AB
- Intervention
- Avatrombopag(drug)
- Enrollment
- 199 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (30)
- Swedish Orphan Biovitrum Research Site 131, Zagreb, Croatia
- Swedish Orphan Biovitrum Research Site 122, Brno, Czechia
- Swedish Orphan Biovitrum Research Site 123, Ostrava, Czechia
- Swedish Orphan Biovitrum Research Site 121, Prague, Czechia
- Swedish Orphan Biovitrum Research Site 124, Prague, Czechia
- Swedish Orphan Biovitrum Research Site 125, Prague, Czechia
- Swedish Orphan Biovitrum Research Site 108, Aschaffenburg, Germany
- Swedish Orphan Biovitrum Research Site 114, Augsburg, Germany
- Swedish Orphan Biovitrum Research Site 116, Augsburg, Germany
- Swedish Orphan Biovitrum Research Site 103, Bad Homburg, Germany
- Swedish Orphan Biovitrum Research Site 106, Berlin, Germany
- Swedish Orphan Biovitrum Research Site 113, Dresden, Germany
- Swedish Orphan Biovitrum Research Site 102, Frankfurt, Germany
- Swedish Orphan Biovitrum Research Site 105, Frankfurt, Germany
- Swedish Orphan Biovitrum Research Site 104, Hanover, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04943042 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07421167A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)Novartis Pharmaceuticals
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals